Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalfyra for fatigue in adults with multiple sclerosis
IRCT20210429051129N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dalfampridine in multiple sclerosis (MS) (2 arms), sponsored by Qazvin University of Medical Sciences. Primary endpoints: Physical aspect of Modified Fatigue Impact Scale, Cognitive aspect of Modified Fatigue Impact Scale and 2 more. Started Jun 2021; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20210429051129N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210429051129N1.